信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

INSIDE INFORMATION ANNOUNCEMENT
UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE YEAR AND THE FOURTH QUARTER OF 2024

This announcement is made by Innovent Biologics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

For the full year of 2024, the total product revenue amounted to more than RMB8.2 billion, representing a robust year-over-year growth of over 40%. In the fourth quarter of 2024, the total product revenue reached above RMB2.0 billion with a year-over-year growth of over 25%. The strong performance was mainly attributable to: (i) the Company's leading position in oncology area and the continued fast growth of major products including TYVYT® (sintilimab injection); and (ii) the strong ramp-up momentum of new products.

The Company anticipates that 2025 will be a year of significant business growth. While continuously growing the exiting product portfolio, the Company will strategically pursue the launch of six innovative drugs and the commercialization of product newly included in National Reimbursement Drug List ("**NRDL**"). The Company anticipates: (i) oncology product portfolio will continue to grow with further enhanced commercial capabilities and efficiency. In 2025, three novel drugs are anticipated to be launched, including Dovbleron® (ROS1 inhibitor), Limertinib (EGFR TKI) for lung cancer, and Jaypirca® (BTK inhibitor) for hematological malignancies; (ii) general biomedicine portfolio will emerge as the other key growth pillar of the Company, unlocking substantial opportunities in chronic diseases. SINTBILO® (anti-PCSK9 monoclonal antibody) has been included in the updated NRDL effective from January 1, 2025. Meanwhile, mazdutide (GCG/GLP-1 dual receptor agonist), teprotumumab (anti-IGF-1R monoclonal antibody), and picankibart (anti-IL-23p19 monoclonal antibody), are currently under review by the National Medical Products Administration of China for approval.

The strong revenue performance and the robust late-stage pipeline have fortified the Company's confidence in achieving its domestic product revenue target of RMB20 billion by 2027. The Company also continues to enhance its operational efficiency under a sustainable and healthy business model.

Meanwhile, in recent years, advancements in the Company's in-house research and development have paved the way for the global development of a competitive pipeline, spanning in the areas of next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC), cardio-vascular and metabolic (CVM), autoimmune, and ophthalmology. Looking forward, the Company is well-positioned for a fruitful 2025 of advancing into new stage of sustainable growth and global innovation, and will continue striving toward the vision of becoming a globally premier biopharmaceutical company.

The financial information set out in this announcement was prepared based on internal management records of the Group which have not been audited or reviewed by external auditors, and as such, the data is for investors' information only. Such data may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company (including but not limited to those published on an annual or semi-annual basis), due to various uncertainties during the process of collection and collating of such data. This announcement does not constitute, nor should it be construed as, an offer or solicitation for the purchase or sale of any securities or financial instruments of the Group.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China
February 6, 2025

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as Executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu and Mr. Shuyun Chen as Independent Non-executive Directors.